SMAIO Stock

Equities

ALSMA

FR0014005I80

Pharmaceuticals

Market Closed - Euronext Paris 05:38:00 2024-05-15 am EDT 5-day change 1st Jan Change
3.5 EUR +2.04% Intraday chart for SMAIO +0.29% +13.64%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2023 5.38M 5.83M Sales 2024 * 5.4M 5.85M Capitalization 17.93M 19.42M
Net income 2023 * -1M -1.08M Net income 2024 * -2M -2.17M EV / Sales 2023 2.99 x
Net cash position 2023 * 3.3M 3.57M Net cash position 2024 * 400K 433K EV / Sales 2024 * 3.25 x
P/E ratio 2023 *
-12.7 x
P/E ratio 2024 *
-8.79 x
Employees 38
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.04%
1 week+0.29%
Current month+9.03%
1 month+10.06%
3 months+15.13%
6 months+47.06%
Current year+13.64%
More quotes
1 week
3.42
Extreme 3.42
3.50
1 month
3.08
Extreme 3.08
3.50
Current year
2.58
Extreme 2.58
3.60
1 year
1.90
Extreme 1.9
3.98
3 years
1.90
Extreme 1.9
5.75
5 years
1.90
Extreme 1.9
5.75
10 years
1.90
Extreme 1.9
5.75
More quotes
Managers TitleAgeSince
Chief Executive Officer - 08-12-28
Director of Finance/CFO - 22-05-31
Chief Tech/Sci/R&D Officer - 20-06-30
Members of the board TitleAgeSince
Director/Board Member - 21-07-29
Director/Board Member 61 21-07-29
Director/Board Member - 21-10-21
More insiders
Date Price Change Volume
24-05-15 3.5 +2.04% 33
24-05-14 3.43 +0.29% 1
24-05-13 3.42 0.00% 333
24-05-10 3.42 -2.29% 301
24-05-09 3.5 +0.29% 37

Real-time Euronext Paris, May 15, 2024 at 05:38 am EDT

More quotes
S.M.A.I.O is specialized in the design, manufacture and marketing of implantable medical devices for the treatment of spinal pathologies. The company offers the Kheiron Spinal Fixation System, a device that incorporates a large number of implants, intended for the immobilization and stabilization of spinal segments as an adjunct to fusion of the thoracic, lumbar and/or sacral spine. In addition, S.M.A.I.O has developed the Keops and Balance Analyzer 3D surgical planning and patient database management software, and the company also offers training programs. Net sales break down by source of revenue between sales of products (95.4%) and services (4.6%). Export accounts for 54.9% of net sales.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.43 EUR
Average target price
5.8 EUR
Spread / Average Target
+69.10%
Consensus

Annual profits - Rate of surprise

1st Jan change Capi.
+13.64% 19.4M
+30.75% 588B
-3.42% 364B
+18.02% 326B
+4.27% 285B
+14.83% 239B
+10.17% 210B
-6.91% 200B
+8.12% 167B
-1.42% 161B
Other Pharmaceuticals
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW